StreetInsider.com News Articles

Form 6-K IceCure Medical Ltd. For: Jun 02

Tue, 02 Jun 2026 08:45:00 -0400

si-local-file:///var/storage/secattach/20260602/26588311.html

Form 6-K IceCure Medical Ltd. For: Jun 02

Tue, 02 Jun 2026 08:45:00 -0400

si-local-file:///var/storage/secattach/20260602/26588311.html

IceCure Medical implements 1-for-30 reverse stock split for nasdaq compliance

Tue, 02 Jun 2026 08:30:58 -0400

IceCure Medical Ltd. (NASDAQ: ICCM) announced it will implement a one-for-thirty reverse stock split of its ordinary shares to meet Nasdaq's $1.00 minimum bid price requirement. The split will take effect when markets open on June 4, 2026.

The reverse split will reduce the number of outstanding ordinary shares from 84,201,034 to approximately 2,806,701 shares. The company's authorized share capital of 2,500,000,000 ordinary shares will remain unchanged under its current articles of association.

IceCure Medical has until November 9, 2026, to cure its non-compliance with Nasdaq listing requirements. The company's shares will continue trading on the Nasdaq Capital Market under the symbol

IceCure Medical implements 1-for-30 reverse stock split for nasdaq compliance

Tue, 02 Jun 2026 08:30:58 -0400

IceCure Medical has until November 9, 2026, to cure its non-compliance with Nasdaq listing requirements. The company's shares will continue trading on the Nasdaq Capital Market under the symbol

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

Tue, 02 Jun 2026 08:30:00 -0400

Proactive Step to Regain Nasdaq Compliance as Part of the Company's Broader Capital Markets Strategy

CAESAREA, ISRAEL, June 2, 2026 /PRNewswire/ -- IceCure Medical Ltd. (the "Company" or "IceCure" or "IceCure Medical") (NASDAQ: ICCM), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it intends to effect a one-for-thirty reverse split (the "Reverse Share Split") of the Company's ordinary shares, no par value per share, (the "Ordinary Shares"), as part of its proactive

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

Tue, 02 Jun 2026 08:30:00 -0400

Proactive Step to Regain Nasdaq Compliance as Part of the Company's Broader Capital Markets Strategy

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

Tue, 02 Jun 2026 08:30:00 -0400

Proactive Step to Regain Nasdaq Compliance as Part of the Company's Broader Capital Markets Strategy

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

Tue, 02 Jun 2026 08:30:00 -0400

Proactive Step to Regain Nasdaq Compliance as Part of the Company's Broader Capital Markets Strategy

Form 6-K IceCure Medical Ltd. For: May 19

Tue, 19 May 2026 08:45:00 -0400

si-local-file:///var/storage/secattach/20260519/26518088.html

Form 6-K IceCure Medical Ltd. For: May 19

Tue, 19 May 2026 08:45:00 -0400

si-local-file:///var/storage/secattach/20260519/26518088.html

IceCure Medical reports kidney cancer study results at medical conference

Tue, 19 May 2026 08:32:57 -0400

IceCure Medical Ltd. (NASDAQ: ICCM) presented clinical data at the European Conference on Interventional Oncology showing treatment outcomes for its ProSense cryoablation system across multiple cancer types.

The ICESECRET trial, a prospective multicenter study, evaluated ProSense for small renal masses in 114 patients with a mean age of 69.1 years. The study reported an 83.9% recurrence-free rate at a median follow-up of 4.0 years. For patients with tumors measuring 3 centimeters or smaller, the recurrence-free rate reached 89.4%. The technical success rate was 92.5% in procedures without anatomical limitations.

A separate study from Turkey examined early-stage breast cancer treatment in 26 patients

IceCure Medical reports kidney cancer study results at medical conference

Tue, 19 May 2026 08:32:57 -0400

A separate study from Turkey examined early-stage breast cancer treatment in 26 patients

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

Tue, 19 May 2026 08:30:00 -0400

At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors ≤3 cm and 83.9% of patients remained recurrence-free at a median follow-up of 4.0 years

Independent breast cancer study reported no residual cancer at 6 and 12 months post-procedure, with 100% of patients reporting excellent cosmetic outcomes

Independent study showed 92.9% reduction in fibroadenoma volume at 12 months post-treatment with ProSense®

FDA clearance of ProSense® in early-stage breast cancer drives expanding global adoption and clinical interest in breast cryoablation